ELECTRONIC LETTER

Investigation of germline *GFRA4* mutations and evaluation of the involvement of *GFRA1*, *GFRA2*, *GFRA3*, and *GFRA4* sequence variants in Hirschsprung disease

S Borrego, R M Fernández, H Dziema, A Niess, M López-Alonso, G Antiñolo, C Eng

J Med Genet 2003;40:e18(<http://www.jmedgenet.com/cgi/content/full/40/3/e18>)

The *RET* proto-oncogene on 10q11.2, which encodes a receptor tyrosine kinase expressed in neural crest and its derivatives, is the susceptibility gene for multiple endocrine neoplasia type 2 (MEN 2), characterised by medullary thyroid carcinoma, pheochromocytoma, and hyperparathyroidism, and one of several susceptibility genes for Hirschsprung disease (HSCR).¹⁻⁴ HSCR is characterised by aganglionosis of the gut resulting from inappropriate and premature apoptosis of the enteric ganglia. Initially, it was believed that approximately 50% of familial HSCR and 30% of isolated HSCR were the result of germline loss of function mutations in the *RET* proto-oncogene^{5,6} (reviewed by Eng and Mulligan⁷). However, these data were obtained with highly selected series of families and patients with HSCR. A population based survey of HSCR cases showed that only 3% of isolated HSCR carried traditional germline *RET* mutations.⁸ In the context of these data and the anecdotal observation that a *RET* codon 45 variant seemed to modify the expression of HSCR in a MEN 2/HSCR family with *RET* codon 618 mutation,⁹ we began to examine the polymorphic alleles at codon 45 and the other coding variants as common low penetrance alleles for HSCR susceptibility. Indeed, we found that certain haplotypes or pairs of haplotypes ("genotypes") comprising specific combinations of *RET* polymorphic sequence variants were highly associated with isolated HSCR.⁹⁻¹¹ These observations were also noted among HSCR populations from elsewhere in the world.¹²⁻¹⁴ These data implied that *RET* and/or loci in proximity to it could act as common low penetrance alleles which predisposed to isolated HSCR.

There are perhaps seven susceptibility genes for syndromic and non-syndromic HSCR.^{3,4,15-25} Among these seven genes, *RET* is considered a major susceptibility gene for HSCR. *RET* is an unusual receptor tyrosine kinase in that it requires one of four co-receptors, *GFRα-1*, *GFRα-2*, *GFRα-3*, and *GFRα-4*, before it can bind one of four specific related ligands, GDNF, neurturin, persefin, and artemin.²⁶⁻⁴³ While germline mutations in the genes encoding GDNF and neurturin, *GDNF* and *NTN*, have been rarely described in HSCR,^{18,21,44} there has yet to be convincing data suggesting that *GFRA1* (10q26), *GFRA2* (8p21), or *GFRA3* (5q31) can act as "traditional" susceptibility genes for HSCR.⁴⁵⁻⁴⁸ Thus, the genes which encode the co-receptors of *RET* are excellent candidates to serve as common low penetrance alleles for predisposition to isolated HSCR as well, and may interact with the *RET* sequence variants, and perhaps other variants, to modulate disease. To test our hypothesis, we examined a population based series of isolated HSCR cases for association with sequence variants within the genes which encode the four known co-receptors of *RET*. In addition, because *GFRA4* (20p12-p13), which encodes one of the four *RET* co-receptors and which is expressed in the derivatives of the neural crest including the enteric nervous system,⁴⁹ has not been evaluated as a traditional susceptibility

Key points

- Hirschsprung disease (HSCR) occurs in 1:5000 live births and is currently acknowledged as having a polygenic aetiology. Originally reported as the major susceptibility gene for both inherited and isolated HSCR, germline loss of function mutations in the *RET* proto-oncogene, encoding a receptor tyrosine kinase on 10q11.2, have only been implicated in 3% of a population based series of HSCR.
- Recently, we and others have shown that germline sequence variants within the *RET* coding sequence are significantly associated with isolated HSCR cases. In fact, when cases were compared to controls, HSCR cases were found to have specific *RET* haplotypes and pairs of haplotypes which were distinct from those of controls. Thus, the genes which encode the four known co-receptors of *RET*, *GFRA1-4*, are excellent candidates to play roles in the aetiology of HSCR.
- It has already been shown that traditional mutations in *GFRA1-3* do not play a prominent role in HSCR. Here, we have found that among 72 isolated HSCR cases from the population base of southern Spain, there were no traditional germline mutations in *GFRA4*. We have also investigated this cohort for associations with sequence variants spanning *GFRA1-4* to search for the possibility that these genes serve to harbour common low penetrance alleles for HSCR.
- None of the sequence variants within these four genes was associated with HSCR compared to controls. Further, no variants considered at single loci or haplotypes or haplotype combinations were associated with clinical parameters. We did find, however, a large germline deletion in *GFRA1* of unknown significance.
- In sum, our data suggest that *GFRA1-4* are not major contributors of high or low penetrance alleles for susceptibility to isolated HSCR. This may reflect their overlapping function.

gene for HSCR, we also performed mutation analysis of the entire gene in our HSCR cohort.

MATERIALS AND METHODS

Subjects

Seventy-two consenting cases of isolated HSCR originating from southern Spain were ascertained within a 16 month period, in accordance with the respective human subjects protection committees. Further, at least one of the two unaffected

parents of each of the 70 isolated HSCR cases also donated their blood for these studies. One hundred and fifteen race matched, geographically matched normal controls were also gathered.

Single nucleotide polymorphism (SNP) and mutation analysis

Genomic DNA was extracted according to standard protocols.^{9 10 50} Genotyping at each SNP locus within *GFRA1*, *GFRA2*, *GFRA3*, and *GFRA4* was performed as previously described, either by SSCP or FRET, and if necessary confirmed with differential restriction digestion or direct sequence analysis.^{10 11 51 52} A total of 14 SNP loci within the four co-receptor genes were examined. Well documented biallelic SNPs at each locus belonging to *GFRA1* (seven loci), *GFRA2* (one locus), and *GFRA3* (two loci)^{46 47 51} were analysed.

Because *GFRA4* had not been previously examined in HSCR, its exons and flanking intronic regions were analysed in their entirety using a combination of SSCP and semi-automated sequence analysis as previously described.⁵³ Four SNPs in *GFRA4* were uncovered using SSCP and confirmed with sequencing (see Results below).

For each subject, haplotypes comprising combinations of alleles at each SNP locus within each gene were formed for every HSCR case and control, where possible. Haplotype formation was made possible because phase could be determined by having available genotypes among HSCR cases and their unaffected parents in a similar manner as previously described for haplotype formation within *RET*.¹¹

Statistical analysis

The frequencies of each allele at each SNP locus was compared between cases and controls using chi-squared analysis with

Yates' correction as previously described.¹⁰ Frequencies of haplotypes across each of the four genes were then compared between cases and controls also using chi-squared analysis with Yates' correction as previously described¹¹; $p < 0.05$ was considered significant. In addition, haplotype frequencies were compared against various demographic and clinical features among all HSCR cases, such as sex, age at diagnosis, and length of segment involved (short segment v long segment disease) using either chi-squared analysis with Yates' correction or Fisher's exact test (two tailed).

RESULTS

Because *GFRA4* had not been previously analysed as a susceptibility gene for HSCR, the exons, respective exon-intron boundaries, and flanking intronic regions were examined in their entirety. Of note, no germline mutations were found among 72 unrelated isolated HSCR cases. We did, however, find four polymorphic sequence variants within the exonic sequences of this gene, c.102G>A (T34T, exon 2), c.711G>A (P237P, exon 5), c.847C>T, and c.867G>A (exon 6, 3'UTR).

The frequencies of the alleles at each of the SNPs at every locus for each of the four co-receptor genes were not significantly different between HSCR cases and controls. Haplotypes could be formed for 63 of the 72 HSCR cases and 77 of the 115 controls. Nonetheless, no particular haplotype was observed to be particularly prevalent among HSCR cases and normal controls. Pairs of haplotype combinations (genotypes) across all four genes were noted and none was found to be particularly associated with cases compared to controls.

Haplotypes across each of the genes were formed and compared to various demographic and clinical parameters in all HSCR cases. No associations were found between specific

Figure 1 (A) Segregation of the polymorphisms of the *GFRA1* gene in a family carrying a deletion in the 5' end of this gene. (B) FRET analysis of -78T>C (5'UTR of *GFRA1*) in the family carrying the *GFRA1* deletion. The homozygous genotype for the wild type allele has a higher melting temperature than the homozygous genotype for the mutant allele (71.9°C v 65.1°C); heterozygotes for this polymorphism show both peaks. (C) Schematic representation of the 5' end of the *GFRA1* gene.

haplotypes across all four genes and sex, age at diagnosis, and length of segment involved.

While examining haplotypes in HSCR cases and their unaffected parents, we initially thought that we had made either technical or administrative errors in one family as the haplotypes of the parents and the proband were not compatible with Mendelian inheritance (fig 1). More specifically, the results of the genotyping of the $-78T>C$ variant, located in the 5'UTR of the *GFRA1* gene, showed discordant results in the patient and his father (fig 1). Haplotyping at *GFRA2*, *GFRA3*, and *GFRA4* and genotyping at 10 other polymorphic microsatellite loci distant from *GFRA1* excluded non-paternity. Thus, we proceeded to perform further analysis of this family and the results showed a large deletion extending from within intron 3 at the 3' end to as 5' as the 5'UTR within *GFRA1*. Surprisingly, analysis of the unaffected father and three unaffected sibs showed this identical deletion (fig 1). Refinement of the *GFRA1* deleted region in this family was carried out by genotyping of three new informative STRs (D10S1211, D10S1907, and D10S0108) as well as by Southern blotting. The 3' boundary of the deletion is delimited by the D10S0108 microsatellite, which is located over 39 kb from the exon 3-intron 3 boundary. In addition, mutational screening in the *RET*, *GNDF*, *NTN*, *GFRA2*, *GFRA3*, *GFRA4*, and *EDNRB* genes was performed in the index patient, in order to find any mutation which explains why the rest of his relatives carrying the same rearrangement were healthy. However, no significant sequence changes were found in any of these genes. The precise functional significance of the *GFRA1* deletion is currently unknown.

DISCUSSION

Like the genes encoding the first three co-receptors of RET, no traditional germline mutations in *GFRA4* were found in HSCR. Thus, none of the four co-receptor genes appears to contribute, to a significant degree, to the aetiology of HSCR, at least in the non-familial form. It is difficult to explain the lack of traditional germline mutations in the four co-receptor genes given the prominent involvement of *RET*, both in the traditional and low penetrance sense, in the pathogenesis of isolated and familial HSCR. One plausible explanation might be the overlapping functions of the co-receptors and cross reactivity of ligands, albeit with different affinities and with some tissue specific differences (see introduction). However, if this were a plausible explanation, it remains to be explained why germline variants in *GFRA1* appear to play low penetrance susceptibility roles in the aetiology of isolated medullary thyroid carcinoma (MTC), at least in Germany.³¹

Because traditional germline mutations in the four *GFRA* genes have not been shown to play pivotal roles in the pathogenesis of HSCR, we examined them for low penetrance alleles predisposing to isolated HSCR. We have comprehensively excluded this possibility by examining associations at the genotype level, haplotype level, and then combined haplotype level. Furthermore, none of the genotypes, single gene haplotypes, or combined haplotypes were associated with clinical presentation.

Each of the known traditional susceptibility genes for HSCR can also be considered candidates to contribute low penetrance alleles of susceptibility or phenotype modification. *RET* is one such example. Given the limitations of sample size and small effects, none of the genes which encode the four co-receptors of RET appears to play a prominent role as a traditional susceptibility gene or a gene which lends low penetrance susceptibility to isolated HSCR. Nonetheless, many other HSCR susceptibility genes exist as candidates, as well as those which encode molecules upstream and downstream of the proteins encoded by the known susceptibility genes for HSCR.

ACKNOWLEDGEMENTS

This work was partially funded by grants R01 HD39058 from the National Institutes of Health, Bethesda, MD (to SB, GA, and CE), P30 CA16058 from the National Cancer Institute, Bethesda, MD (to The Ohio State University Comprehensive Cancer Center), FIS 01/0551 from the Fondo de Investigación Sanitaria, Spain (to SB and GA), and CAA 116/00 from the Consejería de Salud de la Junta de Andalucía, Spain (to SB and GA).

Authors' affiliations

S Borrego, R M Fernández, G Antiñolo, Unidad de Genética Médica y Diagnóstico Prenatal, Hospitales Universitarios Virgen del Rocío, Sevilla, Spain

H Dziema, A Niess, C Eng, Clinical Cancer Genetics and Human Cancer Genetics Programs, Comprehensive Cancer Center, and the Division of Human Genetics, Department of Internal Medicine, The Ohio State University, Columbus, OH, USA

M López-Alonso, Servicio de Cirugía Infantil, Hospitales Universitarios Virgen del Rocío, Sevilla, Spain

C Eng, Cancer Research UK Human Cancer Genetics Research Group, University of Cambridge, Cambridge, UK

Correspondence to: Dr S Borrego, Unidad de Genética Médica, Hospitales Universitarios Virgen del Rocío, Avda Manuel Siurot, Sevilla 41013, Spain; sborrego@hvr.sas.cica.es

REFERENCES

- Mulligan LM, Kwok JBJ, Healey CS, Elsdon MJ, Eng C, Gardner E, Love DR, Mole SE, Moore JK, Papi L, Ponder MA, Telenius H, Tunnacliffe A, Ponder BAJ. Germline mutations of the *RET* proto-oncogene in multiple endocrine neoplasia type 2A. *Nature* 1993;**363**:458-60.
- Eng C, Clayton D, Schuffenecker I, Lenoir G, Cote G, Gagel RF, Ploos van Amstel HK, Lips CJM, Nishisho I, Takai SI, Marsh DJ, Robinson BG, Frank-Raue K, Raue F, Xue F, Noll WW, Romei C, Pacini F, Fink M, Niederle B, Zedenius J, Nordenskjöld M, Komminoth P, Hendy GN, Gharib H, Thibodeau SN, Lacroix A, Frilling A, Ponder BAJ, Mulligan LM. The relationship between specific *RET* proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2: International *RET* Mutation Consortium analysis. *JAMA* 1996;**276**:1575-9.
- Edery P, Lyonnet S, Mulligan LM, Pelet A, Dow E, Abel L, Holder S, Nihoul-Fekété C, Ponder BAJ, Munnich A. Mutations of the *RET* proto-oncogene in Hirschsprung's disease. *Nature* 1994;**367**:378-80.
- Romeo G, Ronchetto P, Luo Y, Barone V, Seri M, Ceccherini I, Pasini B, Boccardi R, Lerone M, Kääriäinen H, Martucciello G. Point mutations affecting the tyrosine kinase domain of the *RET* proto-oncogene in Hirschsprung's disease. *Nature* 1994;**367**:377-8.
- Angrist M, Bolk S, Thiel B, Puffenberger EG, Hofstra RM, Buys CHCM, Cass DT, Chakravarti A. Mutation analysis of the *RET* receptor tyrosine kinase in Hirschsprung disease. *Hum Mol Genet* 1995;**4**:821-30.
- Attié T, Pelet A, Edery P, Eng C, Mulligan LM, Amiel J, Boutrand L, Beldjord C, Nihoul-Fekété C, Munnich A, Ponder BAJ, Lyonnet S. Diversity of *RET* proto-oncogene mutations in familial and sporadic Hirschsprung disease. *Hum Mol Genet* 1995;**4**:1381-6.
- Eng C, Mulligan LM. Mutations of the *RET* proto-oncogene in multiple endocrine neoplasia type 2, related sporadic tumours and Hirschsprung diseases. *Hum Mutat* 1997;**9**:97-109.
- Svensson PJ, Molander JL, Eng C, Anvret M, Nordenskjöld A. Low frequency of *RET* mutations in Hirschsprung disease in Sweden. *Clin Genet* 1998;**54**:39-44.
- Borrego S, Eng C, Sánchez B, Sáez ME, Navarro E, Antiñolo G. Molecular analysis of *RET* and *GNDF* genes in a family with multiple endocrine neoplasia type 2A and Hirschsprung disease. *J Clin Endocrinol Metab* 1998;**83**:3361-4.
- Borrego S, Sáez ME, Ruiz A, Gimm O, Lopez-Alonso M, Antiñolo G, Eng C. Specific polymorphisms in the *RET* proto-oncogene are over-represented in individuals with Hirschsprung disease and may represent loci modifying phenotypic expression. *J Med Genet* 1999;**36**:771-4.
- Borrego S, Sáez ME, Ruiz A, Gimm O, Gao X, Lopez-Alonso M, Hernandez A, Wright FA, Antiñolo G, Eng C. *RET* genotypes comprising specific haplotypes of polymorphic variants predispose to isolated Hirschsprung disease. *J Med Genet* 2000;**37**:572-8.
- Fitze G, Schreiber M, Kuhlisch E, Schackert HK, Roesner D. Association of the *RET* proto-oncogene codon 45 polymorphism with Hirschsprung disease. *Am J Hum Genet* 1999;**65**:1469-73.
- Ceccherini I, Griseri P, Sancandi M, Patrone G, Boccardi R, Hofstra R, Ravazzolo R, Romeo G, Devoto M. Decreased frequency of a neutral sequence variant of the *RET* proto-oncogene in sporadic Hirschsprung disease. *Am J Hum Genet* 1999;**65**:A266.
- Sancandi M, Ceccherini I, Costa M, Fava M, Chen B, Wu Y, Hofstra R, Laurie T, Griffiths M, Burge D, Tam PK. Incidence of *RET* mutations in patients with Hirschsprung's disease. *J Pediatr Surg* 2000;**35**:139-42.
- Puffenberger EG, Hosoda K, Washington SS, Nakao K, de Wit D, Yanagisawa M, Chakravarti A. A missense mutation of the endothelin B receptor gene in multigenic Hirschsprung's disease. *Cell* 1995;**79**:1257-66.

- 16 **Amiel J**, Attié T, Jan D, Pelet A, Edery P, Bidaud C, Lacombe D, Tam P, Simeoni J, Flori E, Nihoul-Fékété C, Munnich A, Lyonnet S. Heterozygous endothelin receptor B (*EDNRB*) mutations in isolated Hirschsprung disease. *Hum Mol Genet* 1996;**5**:355-7.
- 17 **Auricchio A**, Casari G, Staiano A, Ballabio A. Endothelin-B receptor mutations in patients with isolated Hirschsprung disease from a non-inbred population. *Hum Mol Genet* 1996;**5**:351-4.
- 18 **Salomon R**, Attié T, Pelet A, Bidaud C, Eng C, Amiel J, Sarnacki S, Goulet O, Ricour C, Nihoul-Fékété C, Munnich A, Lyonnet S. Germline mutations of the RET ligand, GDNF, are not sufficient to cause Hirschsprung disease. *Nat Genet* 1996;**14**:345-7.
- 19 **Angrist M**, Bolk S, Halushka M, Lapchak PA, Chakravarti A. Germline mutations in glial cell line-derived neurotrophic factor (*GDNF*) and *RET* in a Hirschsprung disease patient. *Nat Genet* 1996;**14**:341-4.
- 20 **Bidaud C**, Salomon R, Vancamp G, Pelet A, Attié T, Eng C, Bonduelle M, Amiel J, Nihoul-Fékété C, Willems PJ, Munnich A, Lyonnet S. Endothelin-3 gene mutations in isolated and syndromic Hirschsprung disease. *Eur J Hum Genet* 1997;**5**:247-51.
- 21 **Doray B**, Salomon R, Amiel J, Pelet A, Touraine R, Billaud M, Attié T, Bachy B, Munnich A, Lyonnet S. Mutation of the RET ligands, neurturin, supports multigenic inheritance in Hirschsprung disease. *Hum Mol Genet* 1998;**7**:1449-52.
- 22 **Pingault V**, Bondurand N, Kuhlbrodt K, Goerich DE, Préhu M-O, Puliti A, Herbarth B, Hermans-Borgmeyer I, Legius E, Matthijs G, Amiel J, Lyonnet S, Ceccherini I, Romeo G, Clayton Smith J, Read AP, Wegner M, Goossens M. *SOX10* mutations in patients with Waardenburg-Hirschsprung disease. *Nat Genet* 1998;**18**:171-3.
- 23 **Southard-Smith EM**, Kos I, Pavan WJ. *Sox10* mutation disrupts neural crest development in *Dom* Hirschsprung mouse model. *Nat Genet* 1998;**18**:60-4.
- 24 **Wakamatsu N**, Yamada Y, Yamada K, Ono T, Nomura N, Taniguchi H, Kitoh H, Mutoh N, Yamanaka T, Mushiake K, Kato K, Sonata S, Nagaya M. Mutations in *SIP1*, encoding Smad interacting protein-1, cause a form of Hirschsprung disease. *Nat Genet* 2001;**27**:369-70.
- 25 **Amiel J**, Espinosa-Parilla Y, Steffan J, Gosset P, Pelet A, Prieru M, Boute O, Choiset A, Lacombe D, Philip N, Le Merrer M, Tanaka H, Till M, Touraine R, Toutain A, Vekemans M, Munnich A, Lyonnet S. Large-scale deletions and *SMAD1P1* truncating mutations in syndromic Hirschsprung disease with involvement of midline structures. *Am J Hum Genet* 2001;**69**:1370-7.
- 26 **Trupp M**, Arenas E, Fainzilber M, Nilsson AS, Sleber BA, Grigoriou M, Kilkeny C, Salazar-Grueso E, Pachnis V, Arumae U, Sariola H, Saarma M, Ibanez CF. Functional receptor for GDNF encoded by the *c-ret* proto-oncogene. *Nature* 1996;**381**:785-9.
- 27 **Pichel JG**, Shen L, Sheng HZ, Granholm A-C, Drago J, Grinberg A, Lee EJ, Huang SP, Saarmas M, Hoffer BJ, Sariola H, Westphal H. Defects in enteric innervation and kidney development in mice lacking GDNF. *Nature* 1996;**382**:73-6.
- 28 **Jing S**, Wen D, Yu Y, Holst PL, Luo Y, Fang M, Tamir R, Antonio L, Hu Z, Cupples R, Louis JC, Hu S, Altrick BW, Fox GM. GDNF-induced activation of the Ret protein tyrosine kinase is mediated by GDNFR- α , a novel receptor for GDNF. *Cell* 1996;**85**:1113-24.
- 29 **Treanor JJS**, Goodman L, de Sauvage F, Stone DM, Poulsen KT, Beck CD, Gray C, Armanini MP, Pollock RA, Hefti F, Phillips HS, Goddard A, Moore MW, Bui-Bello A, Davies AM, Asai N, Takahashi M, Vanden R, Henderson CE, Rosenthal A. Characterization of a multicomponent receptor for GDNF. *Nature* 1996;**382**:80-3.
- 30 **Lin LFH**, Doherty DH, Lile JD, Bektesh S, Collins FS. GDNF: a glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons. *Science* 1993;**260**:1130-2.
- 31 **Birmingham N**, Hillermann R, Gilmour F, Martin JE, Fisher EMC. Human glial cell line-derived neurotrophic factor (GDNF) maps to chromosome 5. *Hum Genet* 1995;**96**:671-3.
- 32 **Kotzbauer PT**, Lampe PA, Heuckeroth RO, Golden JP, Crendon DJ, Johnson EM, Milbrandt J. Neurturin, a relative of glial-cell-line-derived neurotrophic factor. *Nature* 1996;**384**:467-70.
- 33 **Sanicola M**, Hession C, Worley D, Carmillo P, Ehrenfels C, Walus L, Robinson S, Jaworski G, Wei H, Tizard R, Whitty A, Pepinsky RB, Cate RL. GDNF-dependent RET activation can be mediated by two different cell-surface accessory proteins. *Proc Natl Acad Sci USA* 1997;**94**:6238-43.
- 34 **Baloh RH**, Tansey MG, Golden JP, Crendon DJ, Heuckeroth RO, Keck CL, Zimonjic DB, Popescu NC, Johnson EM, Milbrandt J. TrnR2, a novel receptor that mediates neurturin and GDNF signaling through Ret. *Neuron* 1997;**18**:793-802.
- 35 **Klein RD**, Sherman D, Ho WH, Stone D, Bennett GL, Moffat B, Vanden R, Simmons L, Gu Q, Hongo JA, Devaux B, Poulsen K, Armanini M, Nozaki C, Asai N, Goddard A, Phillips H, Henderson CE, Takahashi M, Rosenthal A. A GPI-linked protein that interacts with Ret to form a candidate neurturin receptor. *Nature* 1997;**387**:717-21.
- 36 **Bui-Bello A**, Adu J, Pinón LGP, Horton A, Thompson J, Rosenthal A, Chinchetru M, Buchman VL, Davies AM. Neurturin responsiveness requires a GPI-linked receptor and the Ret receptor tyrosine kinase. *Nature* 1997;**387**:721-4.
- 37 **Davies AM**, Dixon JE, Fox GM, Ibanez CF, Jing SQ, Johnson E, Milbrandt J, Phillips H, Rosenthal A, Saarma M, Sanicola M, Treanor J, Vega QC. Nomenclature for GPI-linked receptors for the GDNF ligand family. *Neuron* 1997;**19**:485.
- 38 **Enokido Y**, de Sauvage F, Hongo JA, Ninkina N, Rosenthal A, Buchman VL, Davies AM. GFR α -4 and the tyrosine kinase Ret form a functional receptor complex for persephin. *Curr Biology* 1998;**8**:1019-22.
- 39 **Jing SQ**, Yu YB, Fang M, Hu Z, Holst PL, Boone T, Delaney J, Schultz H, Zhou RP, Fox GM. GFR-alpha-2 and GFR-alpha-3 are two new receptors for ligands of the GDNF family. *J Biol Chem* 1998;**272**:33111-17.
- 40 **Thompson J**, Doxakis E, Pinon LGP, Strachan P, Bui-Bello A, Wyatt S, Buchman VL, Davies AM. GFR α -4, a new GDNF family receptor. *Mol Cell Neurosci* 1998;**11**:117-26.
- 41 **Trupp M**, Raynoschek C, Belluaro N, Ibanez CF. Multiple GPI-anchored receptors control GDNF-dependent and independent activation of the c-Ret receptor tyrosine kinase. *Mol Cell Neurobiol* 1998;**11**:47-63.
- 42 **Baloh RH**, Tansey MG, Lampe PA, Fahrner TJ, Enomoto H, Simburger KS, Leitner ML, Araki T, Johnson EM, Milbrandt J. Artemin, a novel member of the GDNF ligand family, supports peripheral and central neurons and signals through the GFRalpha-3-RET receptor complex. *Neuron* 1998;**21**:1291-302.
- 43 **Masure S**, Geerts H, Cik M, Hoefnagel E, van den Kieboom G, Tutelaars A, Harris S, Lesage ASJ, Lysens JE, van der Helm L, Verhasselt P, Yon J, Gordon RD. Enavein, a member of the glial cell-line-derived neurotrophic factor (GDNF) family with growth promoting activity on neuronal cells. *Eur J Biochem* 2000;**266**:892-902.
- 44 **Ivanchuk SM**, Myers SM, Eng C, Mulligan LM. De novo mutation of GDNF, ligand for RET/GDNFR- α receptor complex in Hirschsprung disease. *Hum Mol Genet* 1996;**5**:2023-6.
- 45 **Angrist M**, Jing S, Bolk S, Bentley K, Nallasamy S, Halushka M, Fox GM, Chakravarti A. Human *GFR α 1*: cloning, mapping, genomic structure and evaluation as a candidate gene in Hirschsprung disease. *Genomics* 1998;**48**:354-62.
- 46 **Myers SM**, Salomon R, Gössling A, Pelet A, Eng C, von Deimling A, Lyonnet S, Mulligan LM. Absence of germline *GFR α 1* mutations in Hirschsprung disease. *J Med Genet* 1999;**36**:217-20.
- 47 **Onochie CI**, Korngut LM, Vanhorne JB, Myers SM, Michaud D, Mulligan LM. Characterisation of the GFRalpha-3 locus and investigation of the gene in Hirschsprung disease. *J Med Genet* 2000;**37**:669-73.
- 48 **Vanhorne JB**, Gimm O, Myers SM, Kaushik A, von Deimling A, Eng C, Mulligan LM. Cloning and characterization of the human *GFR α 2* locus and investigation of the gene in Hirschsprung disease. *Hum Genet* 2001;**108**:409-15.
- 49 **Timmusk LM**, Saarma M, Airaksinen MS. Expression and alternative splicing of mouse *Gfra4* suggest roles in endocrine cell development. *Mol Cell Neurosci* 2000;**15**:522-3.
- 50 **Mathew CGP**, Smith BA, Thorp K, Wong Z, Royle NJ, Jeffreys AJ, Ponder BAJ. Deletion of genes on chromosome 1 in endocrine neoplasia. *Nature* 1987;**328**:524-6.
- 51 **Gimm O**, Dziema H, Brown JL, Hoang-Vu C, Hinze R, Dralle H, Mulligan LM, Eng C. Over-representation of a germline variant in the gene encoding RET co-receptor GFR α -1 but not GFR α -2 or GFR α -3 in cases with sporadic medullary thyroid carcinoma. *Oncogene* 2001;**20**:2161-70.
- 52 **Ruiz A**, Antiñolo G, Marcos I, Borrego S. Novel technique for scanning of codon 634 of the *RET* proto-oncogene using fluorescence resonance energy transfer and real-time PCR in patients with medullary thyroid carcinoma. *Clin Chem* 2001;**47**:1939-44.
- 53 **Gimm O**, Dziema H, Brown J, de la Puente A, Hoang-Vu C, Dralle H, Plass C, Eng C. Mutation analysis of *NTRK2* and *NTRK3*, encoding two tyrosine kinases, in sporadic human medullary thyroid carcinoma reveals novel sequence variants. *Int J Cancer* 2001;**92**:70-4.